SCHEMBL23883115

SCHEMBL23883115

CCOC(=O)[C@@H]1CCCN(C(=O)CCC2CCN(C(=O)O)CC2)C1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.60
SMN1; SMN2 Q16637 3/20 0.55
HPGD P15428 2/20 0.55
POLB P06746 2/20 0.54
NPC1 O15118 2/20 0.54
TSHR P16473 1/20 0.54
RAB9A P51151 1/20 0.54
ITGB3 P05106 2/20 0.52
ITGA2B P08514 2/20 0.52
F2R P25116 2/20 0.52
CYP3A4 P08684 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C19 P33261 1/20 0.52
HTT P42858 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23883116 1.00 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2HPGDPOLBNPC1
SCHEMBL3455258 0.90 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2HPGDPOLBNPC1
SCHEMBL25453023 0.90 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2HPGDPOLBNPC1
SCHEMBL28917182 0.86 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HPGDPOLBNPC1
SCHEMBL28917184 0.86 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HPGDPOLBNPC1
SCHEMBL4071532 0.83 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2HPGDPOLBNPC1
SCHEMBL23902522 0.81 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2HPGDPOLBNPC1
SCHEMBL14698199 0.81 ITGB3 (0.47) ALDH1A1ITGB3ITGA2BF2RMEN1
Trifluoroacetic Acid SCHEMBL7502226 0.79 ITGB3 (0.58) ALDH1A1POLBITGB3ITGA2BF2R
SCHEMBL27418421 0.78 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2HPGDPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142546-A1 RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING THE ASAN FOUNDATION (KR) 2023-05-11 US disclosed
US-20230129721-A1 STABILIZER FOR RADIOPHARMACEUTICALS AND RADIOPHARMACEUTICAL COMPOSITION COMPRISING THE SAME THE ASAN FOUNDATION (KR) 2023-04-27 US disclosed
EP-4122500-A1 THROMBUS IMAGING RADIOPHARMACEUTICAL AND COMPOSITION The Asan Foundation (KR) 2023-01-25 EP disclosed
CN-115515647-A Radiopharmaceuticals and compositions for thrombus imaging 财团法人峨山社会福祉财团 2022-12-23 CN disclosed
WO-2021201488-A1 THROMBUS IMAGING RADIOPHARMACEUTICAL AND COMPOSITION 재단법인 아산사회복지재단 2021-10-07 WO disclosed
WO-2021201395-A1 STABILIZING AGENT FOR RADIOPHARMACEUTICAL, AND RADIOPHARMACEUTICAL COMPOSITION COMPRISING SAME 재단법인 아산사회복지재단 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142546-A1 RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING SERPINC1, F3, F11 ALDH1A1 1326/4885SMN1; SMN2 3235/4885HPGD 2423/4885
US-20230129721-A1 STABILIZER FOR RADIOPHARMACEUTICALS AND RADIOPHARMACEUTICAL COMPOSITION COMPRISING THE SAME GC, ADORA2B, TBCB ALDH1A1 2274/4885SMN1; SMN2 2552/4885HPGD 1403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.